Articles tagged "Graft function"

2016 American Transplant Congress
A Systematic Over View of Five Year Results of Serial Protocol Kidney Transplant Biopsies.
A. Geraedts, M. Tavakol, F. Vincenti, S. Chandran, Z. Laszik, B. Lee, J. Roberts, M. Sarwal.
Surgery, UCSF, San Francisco, CA.
Background: Protocol biopsies can detect sub-clinical rejection. With declining rates of clinical acute rejection, a systematic review of protocol biopsies can provide clues about other…
2016 American Transplant Congress
Influence of AKIN Stage on the Outcome of Deceased Donor Kidney Transplantation (DDKTx).
I. Qaqish, D. Haakinson, K. Reddy, M. Smith, H. Khamash, H. Raymond.
Mayo Clinic, Phoenix, AZ.
BackgroundTransplanting kidneys from donors with AKI is one of the methods to minimize the disparity between numbers of listed patient and donor pool. Our aim…
2016 American Transplant Congress
Role of Natural Killer Cells in Kidney Transplant Outcome.
E. Carta,¹ R. Littera,² M. Murgia,¹ M. Michittu,¹ B. Onano,¹ G. Piredda,¹ D. Argiolas.¹
¹Renal Transplant Unit, Azienda Brotzu, Cagliari, Italy; ²Regional Transplant Coordination, ASL 8, Cagliari, Italy.
Aim of the study was to evaluate the relationship between killer cell immunoglobulin-like receptor (KIR) phenotype and kidney transplant rejection. NK-target cell interaction depends on…
2016 American Transplant Congress
Alemtuzumab Induction Allows Better Rejection Free Graft Survival in Comparison to Basiliximab Although with Increased Post Transplant Viral Infections.
V. Siddagangaiah,¹ H. Sharma,² N. Lal,¹ J. Rai,¹ M. Howse,¹ D. Ridgway,¹ A. Sharma,¹ A. Hammad,¹ S. Mehra.¹
¹Renal Transplant Surgery, Royal Liverpool and Broadgreen University Hospital, Liverpool, United Kingdom; ²Transplant Surgery, Manchester Royal Infirmary, Manchester, United Kingdom.
Introduction: 3C study concluded that in comparison to basiliximab, alemtuzumab induction reduces the risk of biopsy proven acute rejection (BPAR) in renal transplant recipients. In…
2016 American Transplant Congress
Enhanced Natural Killer Responsiveness Is a Potent Cytotoxic Mechanism Associating to Kidney Allograft Dysfunction and Pathogenic Effects of Donor-Specific Antibodies (DSA).
P. Paul,^1,2 T. Legris,³ C. Picard,⁴ D. Todorova,^1,2 L. Lyonnet,¹ L. Daniel,⁵ B. Dussol,^3,6 V. Moal,³ H. Vacher Coponat,³ Y. Berland,³ F. Dignat-George,^1,2 S. Burtey.^2,3
¹Hematology, Assistance Publique Hopitaux Marseille, Marseille, France; ²UMR-1076, VRCM, Aix Marseille University, INSERM, Marseille, France; ³Nephrology Dialysis Renal Transplantation Center, Assistance Publique Hopitaux Marseille, Marseille, France; ⁴Immunogenetics, Etablissement Français du Sang, Marseille, France; ⁵Anatomy, Pathology, Neuropathology, Assistance Publique Hopitaux Marseille, Marseille, France; ⁶Center for Clinical Investigation, Assistance Publique Hopitaux Marseille, Marseille, France.
While antibody mediated rejection (ABMR) is a major cause of kidney transplant loss, the role of Natural Killer cells (NK) as immune effectors of complement-independent…
2016 American Transplant Congress
Pancreas Transplantation from Pediatric Donors: A UNOS Registry Analysis.
M. Spaggiari, I. Tzvetanov, H. Jeon, E. Benedetti, J. Oberholzer.
Division of Transplantation, University of Illinois at Chicago, Chicago.
Introduction: Major concerns about the utilization of pediatric pancreata are the cumulative islet mass and the increased technical complexity. The primary aim of this study…
2016 American Transplant Congress
Analysis of Local versus Imported Expanded Criteria Donor (ECD) Kidneys: A Single Center Experience with 497 ECD Kidney Transplants.
M. Khan,¹ H. El-Hennawy,¹ A. Farney,¹ J. Rogers,¹ G. Orlando,¹ A. Reeves-Daniel,² A. Palanisamy,² M. Gautreaux,³ S. Iskandar,³ W. Doares,⁴ S. Kaczmorski,⁴ R. Stratta.¹
¹Surgery, Wake Forest, Winston-Salem, NC; ²Internal Medicine, Wake Forest, Winston-Salem, NC; ³Pathology, Wake Forest, Winston-Salem, NC; ⁴Pharmacy, Wake Forest, Winston-Salem, NC.
With the new Kidney Allocation System, broader sharing of expanded criteria donor (ECD) kidneys may occur, which may influence discard rates and survival outcomes. To…
2016 American Transplant Congress
Identification of Biomarkers for Progressive Fibrosis in Renal Transplant Patients Using Novel Chemical Imaging Approaches.
V. Varma,¹ A. Kajdacsy-Balla,¹ S. Akkina,² S. Setty,¹ M. Walsh.¹
¹Pathology, University of Illinois at Chicago, Chicago, IL; ²Nephrology, University of Illinois at Chicago, Chicago, IL.
BackgroundThe main treatment for end-stage renal disease is kidney transplantation, however close monitoring of post-transplant biopsies is required to identify subclinical complications. In this study,…
2016 American Transplant Congress
New Kidney Allocation System: Friend or Foe?
F. Cabeza,² A. Dejman,¹ A. Torres,³ J. Gaynor,² P. Ruiz,² D. Roth,² W. Kupin,² G. Burke,² G. Ciancio,² L. Chen,² R. Vianna,² A. Mattiazzi,² G. Guerra.²
¹Nephrology and Hypertension, University of Miami, Miami, FL; ²Kidney Transplant, Miami Transplant Institute, Miami, FL; ³Internal Medicine, Hospital San Jose Tec de Monterrey, Mexico D.F., Mexico.
BACKGROUND The new kidney allocation (KAS) system was implemented 12/2014 to increase recipient life years gained annually and facilitate the transplantation of harder to match…
2016 American Transplant Congress
A Novel Microfluidic Device for Purification of Pancreatic Islet Preparations.
W. Varhue,¹ L. Langman,² D. Bowers,³ S. Peirce-Cottler,³ N. Swami,¹ K. Brayman.²
¹Electrical and Computer Engineering, University of Virginia, Charlottesville, VA; ²Surgery, University of Virginia, Charlottesville, VA; ³Biomedical Engineering, University of Virginia, Charlottesville, VA.
Purpose: Demonstrate that novel continuous flow microfluidic designs can be utilized to remove contaminating acinar tissue and sort the purified islets, based on size and…